Brickell Biotech, Inc. (BBI) Tops Q2 EPS by $1.43
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 4:05 PM EDTPhase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month
On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023
Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies
BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Brickell or the Company) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,... More
